About Us:
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI.
Address:
275 Shoreline Dr, Suite 500
Redwood City, CA 94065
United States
Phone:
(650) 206-4507
Email:
davelyn@rezolutebio.com
Website:
Brief summary of video content:
Rezolute is on a clear mission to develop transformative therapies for rare diseases, particularly those caused by hyperinsulinism through the company’s insulin receptor modulating antibody, ersodetug. Ersodetug has been used to treat patients with congenital hyperinsulinism through a Phase 2b clinical trial RIZE and currently ongoing Phase 3 trial sunRIZE and patients with tumor hyperinsulinism through an expanded access program for compassionate use. Ersodetug’s safety profile and efficacy are further detailed in the publications/abstracts/posters provided.
Have questions? Please contact:
For any further information, please contact VP of Medical Affairs Davelyn Hood, MD, MBA, BCMAS at davelyn@rezolutebio.com
Enter the MAP Spotlight Raffle